Literature DB >> 15472311

Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.

M A Pfaller1, A Espinel-Ingroff, R N Jones.   

Abstract

A commercially prepared dried colorimetric microdilution panel (Sensititre YeastOne, TREK Diagnostic Systems, Cleveland, Ohio) was compared in three different laboratories with the National Committee for Clinical Laboratory Standards (NCCLS) reference microdilution method by testing two quality control strains and 300 clinical isolates of Candida spp. against fluconazole, voriconazole, posaconazole, and ravuconazole. Reference MIC endpoints were established after 48 h of incubation and YeastOne colorimetric endpoints were established after 24 h of incubation. YeastOne endpoints were determined to be the lowest concentration at which the color in the well changed from red (indicating growth) to purple (indicating growth inhibition) or blue (indicating no growth). Excellent agreement (within two dilutions) between the reference and colorimetric MICs was observed. Overall agreement was 95.4%. Agreement ranged from 92.3% with posaconazole to 98.0% with fluconazole. The YeastOne colorimetric method appears to be comparable to the NCCLS reference method for testing the susceptibility of Candida spp to the new triazoles voriconazole, posaconazole, and ravuconazole.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472311      PMCID: PMC522344          DOI: 10.1128/JCM.42.10.4577-4580.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  Antifungal susceptibility testing. New technology and clinical applications.

Authors:  M A Pfaller; W L Yu
Journal:  Infect Dis Clin North Am       Date:  2001-12       Impact factor: 5.982

2.  Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; H Huynh; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

3.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

4.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; S Killian; H A Norris; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

6.  Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland.

Authors:  Lena Rós Asmundsdóttir; Helga Erlendsdóttir; Magnús Gottfredsson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

7.  Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species.

Authors:  G Morace; G Amato; F Bistoni; G Fadda; P Marone; M T Montagna; S Oliveri; L Polonelli; R Rigoli; I Mancuso; S La Face; L Masucci; L Romano; C Napoli; D Tatò; M G Buscema; C M C Belli; M M Piccirillo; S Conti; S Covan; F Fanti; C Cavanna; F D'Alò; L Pitzurra
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years.

Authors:  Yee-Chun Chen; Shan-Chwen Chang; Kwen-Tay Luh; Wei-Chuan Hsieh
Journal:  J Antimicrob Chemother       Date:  2003-05-29       Impact factor: 5.790

10.  European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region.

Authors:  A M Tortorano; E Biraghi; A Astolfi; C Ossi; M Tejada; C Farina; S Perin; C Bonaccorso; C Cavanna; A Raballo; A Grossi
Journal:  J Hosp Infect       Date:  2002-08       Impact factor: 3.926

View more
  23 in total

1.  Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

2.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

3.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

4.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.

Authors:  M A Pfaller; V Chaturvedi; D J Diekema; M A Ghannoum; N M Holliday; S B Killian; C C Knapp; S A Messer; A Miskov; R Ramani
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

5.  Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents.

Authors:  Stefan Riedel; Stephen W Eisinger; Lisa Dam; Paul D Stamper; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

6.  Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates.

Authors:  Hedda Luise Koehling; Birgit Willinger; Jan Buer; Peter-Michael Rath; Joerg Steinmann
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

7.  Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.

Authors:  Joanne Peter; Derek Armstrong; Caron A Lyman; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

9.  Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

10.  Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.

Authors:  Ana Espinel-Ingroff; E Canton; J Peman; M G Rinaldi; A W Fothergill
Journal:  J Clin Microbiol       Date:  2009-07-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.